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Melanin pigmentation of the vertebrate integument is regulated by melano-
phore-stimulating hormone (MSH) which originates from the pars intermedia of
the pituitary gland (1). Early experiments established that MSH release, as for
other pituitary secretions, was under control by the hypothalamus (2). Similar to
prolactin release (3), MSH secretion is under an inhibitory control by the hypo-
thalamus (4). Hypothalamic lesions (5, 6) or ectopic transplantation (7) of the
pituitary leads to hypertrophy of the pars intermedia and elevated levels of circulat-
ing MSH (8). Both a direct neuronal (adrenergic) inhibition (9) and a hypo-
thalamic MSH release-inhibiting factor (MRIF, 10) may possibly regulate pars
intermedia function. It is not yet clear whether there is a functional relationship
between these two suggested mechanisms of pars intermedia regulation or whether
one or both of these inhibitory mechanisms is operative in each of the vertebrate
classes (1 ).
Whatever the nature of the hormone(s) or neurotransmitter(s) controlling MSH
secretion, these first messengers (12) probably interact directly with the pars inter-
media cells. An understanding of their mechanisms of action, as for other chemical
messengers, is clearly an important goal of the physiologist interested in the control
of melanin pigmentation. An attempt will be made here to discuss and evaluate
th- experimental data relating to the factors and mechanisms said to be involved
in pars intermedia cell regulation.
MATERIALS AND METHODS
With the exception of the rat, both sexes of each animal species were utilized.
Only female rats, however, were employed in the studies reported here. The frogs,
Rana pipiens (80-190 g) and R. catesbeiana (180-210 g) and the toad, Bufo
marinus (200-280 g) were purchased from Southwestern Scientific Supply Com-
pany (Tucson, AZ). Hamsters (90-115 g) were obtained from the Arizona Pet
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Farm (Tucson, AZ). Sprague-Dawley-derived rats (140-210 g) were reared in
our own facilities.
Pituitary removal and incubation. Pituitaries were removed from the animal im-
mediately after decapitation by guillotine and placed in a Ca2+-free medium for
preincubation as described previously (13). Rat and hamster pituitaries were in-
cubated at 320C in a Krebs-Ringer bicarbonate (KRB), Trizma-buffered to pH
7.5. An amphibian Ringer Trizma-buffered to pH 7.1 was employed at 270C for
the frog and toad pars intermedia. All glands were incubated in a Dubnoff meta-
bolic shaker under a 95% 02, 5% CO2 atmosphere. Incubations were of 2-, 4-,
6-, or 8-hr duration.
Ionic and related pharmacological studies. Ion-deficient media (Ca2+-free, K+-
free) and media containing the cardiac glycoside, ouabain (Sigma Chemical Co.)
were prepared as described previously (13). Cytochalasin B (Imperial Chemical
Industries) was dissolved in dimethyl sulfoxide solution (10 mg cytochalasin B/ml
DMSO) and brought to its final concentration by an addition of the appropriate
Ringer. Colchicine (Sigma Chemical Co.) and the Vinca alkaloids, vinblastine and
vincristine sulfate (Lilly Research Laboratories), were used.
Hypothalamic tissue extracts. The hypothalamus (minus median eminence) was
removed according to previously published methods (14) and placed in an ice
bath in a ratio of three hypothalami per milliliter of Ringer and then homogenized.
After centrifugation, the supernatant fraction was divided equally with one half
boiled, at 1000C for 10 min) and the other half untreated. Both supematant frac-
tions (boiled, unboiled) were then used as incubation media. Experiments were
also designed to test for possible enzymatic activity of the crude (unboiled) hypo-
thalamic extract. Two groups (four glands each) of pituitaries were incubated in
control Ringer to allow for a normal release of MSH. After a normal 2-hr incuba-
tion period, the incubation medium of both groups was pooled and subsequently
divided into two 4-ml aliquots. One aliquot served as a control while the other
was used to homogenize freshly removed hypothalamic tissue. Both aliquots were
then placed in the metabolic shaker for a second 2-hr incubation and then bio-
assayed. In addition, acid extracts were prepared by removing the hypothalamic
tissue and placing them directly into 1 ml of 0.1 N HCI followed by homogeniza-
tion and centrifugation. The supernatant fluid was then neutralized to pH 7.1 by
the addition of Trizma-buffered Ringer and used as an incubation medium.
Peptides. Highly purified synthetic tocinoic acid
(L-Cys-L-Tyr-L-Ile-L-Gln-L-Asn-L-CyS-OH)
and its amide, tocinamide
(L-Cys-L-Tyr-L-Ile-L-Gln-L-Asn-L-Cys-NH2)
were prepared by published methods (15, 16) as was the crystalline tripeptide,
L-Pro-L-Leu-Gly-NH2 (17). These structures were then lyophilized with lactose
as carrier. Fresh solutions of these peptides were prepared on the day of testing.
Bioassay. The amount of MSH activity in the media following pituitary incuba-
tion was determined by the in vitro frog-skin bioassay for MSH as previously de-
scribed (13) which utilized the photoelectric reflectance method of Shizume et al.
(18) and Wright and Lerner (19). The media were usually diluted with amphibian
Ringer to give final concentrations of one pituitary secretion per 200 or 400 ml
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of Ringer (whatever concentration gave a submaximal skin-darkening response).
The values reported represent the mean (±SE) darkening response of eight or
more frog skins used for each bioassay. Since, in addition to MSH, some experi-
mental media contained either EDTA, ouabain, etc., it was necessary, when possi-
ble, to add a similar amount of these agents to the control solutions to be
bioassayed.
Statistics. The Student t test for paired observations was used throughout to de-
termine significance.
RESULTS
Melanophore-stimulating hormone (MSH) release is normally under an inhibi-
tory control by the hypothalamus and there is a spontaneous release of the hor-
mone into the medium from the isolated pituitary (rat, mouse (13), hamster (20),
or pars intermedia (frogs, Rana pipiens, Rana catesbeiana; toad, Bufo marinus
(20). This in vitro release of MSH can be reversibly inhibited by the removal
of either calcium or potassium ions from the medium (Fig 1A, B). A Ca2+ require-
ment for hormone release was demonstrated for all species studied (including the
lizard Anolis carolinensis, 13) as was the K+ ion (except in the mouse). These
latter results using K+-free media suggested the possible role of a Na+-K+ pump
(active transport) mechanism in the release of MSH. This was confirmed by the
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FIG. 1. Frog (R. pipiens) pars intermedia were incubated for 2 hr in a Ca2'-free medium
plus EDTA (A), a K+-deficient medium (B), or in the cardiac glycoside, ouabain, at 10-4
g/ml (C). In all cases, there was a near-total inhibition of MSH release compared to
controls. A total of 36 pituitaries (four per experimental group) were utilized. MSH secretion
was inhibited by cytochalasin B (5 X 10-' g/ml) but not by colchicine (10-' g/ml) by
6-hr incubation in the presence of these agents (D). Each value represents the mean (+ SE)
darkening response of eight frog skins to the MSH contained in the incubation media.
P values are noted above the bars where inhibition of hormone release compared to the
control was significant.REGULATION OF MSK RELEASE 605
use of the cardiac glycoside, ouabain, to further test this hypothesis. Ouabain (and
the related glycoside, strophanthin K) strongly inhibited (Fig. 1C), reversibly and
in a dose-related manner (13), the release of MSH from both mammalian and
amphibian pituitaries. It is of interest that both a K+-free medium and ouabain
failed to inhibit MSH release from the mouse pituitary, and this is apparently con-
sistent with other investigations using cardiac glycosides on this rodent.
Both microtubules and microfilaments have been linked with some secretory pro-
cesses (21-23). Certain so-called microtubular-specific (colchicine) and microfila-
ment-specific (cytochalasin B) disruptive agents were used to test their possible
effects on MSH secretion. Incubation of frog pituitaries in low levels (5 X 10-8
g/ml) of cytochalasin B resulted in strong inhibition of MSH release (Fig. 1D).
The specificity of this blockade to hormone release was demonstrated by the failure
of colchicine (Fig. 1D) or Vinca alkaloids (vinblastine, vincristine [24]) to simi-
larly inhibit MSH release even at high (10-3 g/ml) concentrations. Whether these
results implicate a role for microfilaments (rather than microtubules) in the mecha-
nism of acute release of MSH remains to be determined. Recent evidence (25)
from other cellular systems links the effects of cytochalasin to transmembrane
transport mechanisms.
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FIG. 2. Rana pipiens pars intermedia were incubated for 2 hr in crude hypothalamic
extracts (A), in hypothalamic extracts which had been boiled (B), or in acid extracts
of the hypothalamus (C). Only the crude-extract preparation produced a decrease in MSH
activity in the medium (A). Next, the incubation medium taken after a normal 2-hr pituitary
release of MSH was divided into two equal volumes, one of which was used to homogenate
hypothalamic tissue (see Methods for details). Both preparations were then returned to
the incubator for another 2-hr period and then bioassayed. Again, the medium with crude
extract (D) showed a dramatic drop in MSH activity, whereas this loss of MSH activity
was not evident in the boiled extract (E). These results strongly suggest MSH degradation
by enzymatic action of the crude brain extract (A,D) rather than an inhibition of hormone
release. A total of 40 pars intermedia, four per experimental group, were utilized. Each
bar represents the mean (±+SE) darkening response of eight frog skins to the MSH in
the incubation medium under each experimental condition,HADLEY, BOWER, AND HRUBY
TABLE 1
EFFECTS OF LOWERED pH ON THE RELEASE OF MSH FROM THE FROG PARS INTERMEDIAa
Percent darkening Percent
Incubation P inhibition
time (hr) pH 7.1 pH 6.9 of release P
2 33 ± 1.9 20 ± 1.5 39% <0.001
4 36 ± 2.9 18 ± 1.8 50% <0.001
4 39 ± 3.5 28 ± 3.3 28% <0.05
6 37 ± 3.2 24 ± 2.7 35% <0.01
a Amphibian Ringer was Trizma buffered to pH 7.1 and 6.9 and the stability of the pH was moni-
tored throughout the duration of each incubation. Four R. pipiens pars intermedia were incubated
under each experimental condition. Results are reported as the mean (± SE) darkening response of
eight frog skins to the MSH released into the incubation medium under the two conditions of pH.
Previous in vitro results (14, 20, 26, 27) showed that incubation of pituitaries
in hypothalamic extracts resulted in decreased amounts of bioassayable MSH (Fig.
2A). Unfortunately, these past studies (with few exceptions, 28) failed to rule
out other possible factors that might contribute to decreased amounts of MSH in
the incubation media. Neither boiled nor acid-extracted hypothalami significantly
decreased the amount of bioassayable MSH in the media (Fig. 2B, C). These re-
sults strongly suggested an enzymatic breakdown of released MSH. Further evi-
dence for this was provided by the observation (Fig. 2D, E) that crude (unboiled)
hypothalamic extracts destroyed the MSH activity of added MSH, a result which
was not obtained by similar incubations with boiled extracts. These results do not,
however, rule out the possibility that boiling or acid extraction also destroy the
activity of a postulated melanophore-stimulating hormone release-inhibiting factor
(MRIF). These results, however, do stand in contrast to those of Kastin (28)
who has reported (from one in vitro study) that boiled extracts still inhibit MSH
release under conditions of long-term incubation.
Various procedures have been undertaken in our laboratory to determine the
optimal in vitro conditions for the study of MSH release. Lowering of the pH of
amphibian Ringer from pH 7.1 to 6.9 produces a considerable drop in bioassayable
MSH (Table 1) from the frog pars intermedia. Extended incubations (8-hr) of
pituitaries in Ca2+-free media or in hypothalamic extracts result in an elevation
of MSH within homogenates of frog pars intermedia (Fig. 3). These data possibly
suggest that factors which cause a decreased release of MSH result in a higher
level of MSH within pars intermedia cells. In the present experiment (Fig. 3),
although the control and Ca2+-free media maintained a stable pH of 7.1, the pH
of the hypothalamic extract continually dropped to a pH of 7.0 or slightly below.
These results using extracts do not, therefore, allow one to determine un-
equivocally whether the elevation of pituitary MSH results from a lowered pH
(as in Table 1) or the possible existence of hypothalamic MRIF.
Recent studies, both in vivo and in vitro, have provided evidence that the side
chain of oxytocin, L-Pro-L-Leu-Gly-NH2 is the MRIF (29). Other workers (30)
isolating this same tripeptide, as well as a pentapeptide (Pro-His-Phe-Arg-Gly-
NH2) (31), from bovine hypothalami and using different in vivo methods have
shown that both of these peptides possess MRIF activity (32). In a previously
published study (14) employing the ring structure of oxytocin, tocinoic acid
606REGULATION OF MSK RELEASE
Z ~~~~~~~~~~~~~~~~~~~~~~~<0.001 t: t:000 | tS~~~~~~~~~~~~00
<~ 30<00
%X.~~~~~~~~~~~~~~~~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
20
I0
1/2400 1/4800 1/9600 1/19,200
PITUITARY HOMOGENATE /ml RINGER
FIG. 3. R. pipiens pars intermedia were incubated for 8 hr in a normal Ringer, in the
Ca2'-free EDTA Ringer, and in crude hypothalamic extracts. Glands were transferred to
fresh media or extract after 4-hr incubation. After another 4 hr of incubation, the pituitaries
were removed, rinsed, and homogenized in normal Ringer. Each homogenate was then diluted
(by the additional Ringer) to the concentrations noted and then bioassayed. Each bar repre-
sents the mean (±+SE) darkening response of eight frog skins to the MSH activity of
the pituitary homogenates at the various dilutions indicated. Glands incubated in a Ca2'-free
medium and in the crude hypothalmic extract showed higher MSH activity than did pituitaries
incubated in normal Ringer. P values are indicated above the bars where a significant increase
in pituitary MSH activity over controls occurred.
(L-Cys-L-Tyr-L-Ile-L-Gln-L-Asn-L-Cys-OH), a potent inhibition of MSH release
was shown in both the rat (Fig. 4A) and the toad, B. marinus (Fig. 4C). The
frog R. pipiens, however, was found to be refractory to this neurohypophyseal ring
compound (Fig. 4B) while at the same time showing a high sensitivity to a cal-
cium-deficient medium.
In all species studied, with the exception of the frog R. pipiens as previously
indicated (20), we were also able to demonstrate an inhibition of MSH release
(Fig. 5) with tocinamide, the amide of tocinoic acid. However, when utilizing the
synthetic tripeptide (suggested by others to be the MRIF [29, 30]) no such inhibi-
tion of MSH release could be shown (Fig. 5) in any of the mammals or amphibians
which had evidenced such a high sensitivity to the oxytocin ring compounds
(tocinoic acid, tocinamide). Again, MSH release from pituitaries of Rana pipiens
(suggested by the in vivo methods of other workers [32], to be sensitive to this
peptide) was not inhibited (Fig. 5) by the synthetic tripeptide.
DISCUSSION
Some of the earliest endocrine experiments clearly established (33-36) that the
pituitary gland was in some way involved in the control of integumental melanin
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FIG. 4. Tocinoic acid (10- g/ml) inhibited MSH release from the rat (A) and the
toad Bufo marinus (C) pituitary but was without effect on the frog R. pipiens (B). Within
the same experiment MSH release could be inhibited by Ca'+-free media (B) in the frog
as it was in the rat (A) and the toad (C). Incubations were of 4-hr duration. Each
bar represents the mean (+SE) darkening response of eight frog skins to the MSH released
into the incubation medium from four pituitaries under each experimental condition. Signifi-
cance (P value) is noted above the bars where an inhibition of MSH release occurred.
pigmentation. Other investigations soon demonstrated that integumental pigment
cells were controlled by a hormone of pituitary origin (37) which was shown (38)
to be specifically localized within the pars intermedia. This melanophore (melano-
cyte)-stimulating hormone (MSH) can affect skin pigmentation in all vertebrate
groups from cyclostomes to man (except possibly that of birds [39]). The release
of MSH is normally regulated (1) by environmental cues such as temperature,
humidity, and light, the latter cue being received through the eyes (and possibly
the pineal [40, 41]). This information conveyed through neuronal and synaptic
transmission is ultimately received by the hypothalamus. How the hypothalamus
in turn regulates the release of pituitary MSH is presently the concern of many
investigators.
Etkin showed that MSH release was no longer inhibited when pituitaries were
transplanted to an ectopic site (2). Pituitary transplantation or lesioning (5) of
the hypothalamus results in hypertrophy of the pars intermedia (6, 7) which is
reflected in an increase in melanin pigmentation of the skin, the latter apparently
resulting from increased circulating levels of plasma MSH.
Etkin suggested that inhibition of MSH release was regulated by neurosecretory
neurons which directly penetrate from the hypothalamus into the substance of the
pars intermedia (42). Electrophysiological studies (40, 41 ) as well as brain injec-
tions of neurotransmitters (9) have implicated both acetylycholine and a catechola-
mine, most probably norepinephrine, in the control of MSH release. An adrenergic
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FIG. 5. Tocinamide inhibited the in vitro release of MSH from the pituitaries of the
animals noted except the frog R. pipiens. The tripeptide, L-Pro-L-Leu-Gly-NH2, was without
such inhibitory action of MSH release in any of the species studied. Each bar represents
the MSH released from four pituitaries. Values represent the mean (±SE) darkening response
of eight frog skins to the MSH released under each experimental condition. Incubations
were of 4-hr duration. The P values are noted above the bars where an inhibitory activity
was significant. All concentrations of tocinamide or the tripeptide are in grams per milliliter.
plexus (43) has been visualized by histological means within the pars intermedia
of a number of vertebrates (including that of mammals; see 39, for references).
Ultrastructural studies have described the presence of both adrenergic and neuro-
secretory neurons within the vertebrate pars intermedia (44, 45). The individual
and integrated contributions of neurosecretory, adrenergic, and cholinergic neurons
in MSH release control are yet to be precisely defined. The possible involvement
of the pineal and a pineal hormone in the regulation of MSH release (40, 46,
47) further complicates the picture.
In addition to a direct neuronal influence on pars intermedia cell release of MSH,
hypothalamic inhibiting and releasing factors are implicated in the regulation of
MSH release. Extracts of the hypothalamus are reported (10, 48) to inhibit MSH
release. The presence of an MSH-releasing factor (MRF) in the hypothalamus
in addition to an inhibiting factor (MRIF) has been reported (49-51). More
recently, there have been several publications on the structural nature of these pur-
ported hypothalamic factors (29-31, 51, 52).
As already pointed out in this paper and elsewhere (20), tocinoic acid and es-
pecially tocinamide are quite active in inhibiting MSH release in vitro from pitu-
itaries of the mammals studied (rats and hamsters) and some of the amphibians
studied (Bufo marinus, Rana catesbeiana), but are not active in others (Rana
pipiens). Thus, no claims were made that these peptides are the physiological
MRIF. On the other hand, based on in vitro and in vivo experiments (29, 30),
it was suggested that L-Pro-L-Leu-Gly-NH2, the side peptide from oxytocin, is
MRIF. The same peptide, isolated from bovine hypothalamic extracts and based
on a different in vivo assay (32), was suggested to be MRIF. Other attempts,
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however, to show MRIF-like activity for L-Pro-L-Leu-Gly-NH, in a number of
different animals and assays (14, 20, 53) were unsuccessful as no MSH-release
inhibition could be observed. To further complicate the issue a report has appeared
(51) that Cys-Tyr-Ile-Gln-Asn-OH, a pentapeptide portion from the ring of oxy-
tocin, stimulates release of MSH in vivo. Furthermore, a second peptide, Pro-His-
Phe-Arg-Gly-NH2, has been isolated from bovine hypothalamic extracts and is said
to possess some MRIF-like activity (31). These various reports raise a number
of important questions: (1) Are any of these peptides the real MRIF? (2) What
is the physiological and pharmacological significance of these results? (3) How
is MSH controlled by the hypothalamus? These interrelated questions will now
be discussed.
First of all, we do not believe that there is conclusive evidence that any of the
peptides mentioned in the preceding paragraph correspond to the natural MRIF(s).
Tocinoic acid and tocinamide, peptides which are remarkably effective and
specific inhibitors of MSH release in vitro in mammals, have variable or no in-
hibitory activity in amphibians where a bona fide MRIF might be anticipated to
be most active (since frogs, for example, rapidly change color in response to
MSH). Furthermore, these peptides have neither been searched for nor found in
hypothalamic extracts. Most interesting relative to the structural nature of hypo-
thalamic peptides is the recent report that pressinoic acid (the ring of vasopressin)
has "potent corticotrophin-releasing activity" (54).
On the other hand, although L-Pro-L-Leu-Gly-NH2 has been found in hypothala-
mic extracts, this is not surprising since the most probable part of oxytocin that
might be expected to be found in hypothalamic extracts would be L-Pro-L-Leu-
Gly-NH2, a peptide which would be relatively stable to most of the common exo-
peptidases. In any case, we believe that the in vivo assay methods which have
been reported to measure MRIF-like activity of hypothalamic extracts and the
tripeptide are inadequate and to some extent mutually contradictory. Furthermore,
we have been unable to repeat (14, 20) the in vitro activity reported (29) for
the tripeptide. In the assay method of Celis et al. (29), depletion of pituitary MSH
after treatment with hypothalmic extracts is taken to indicate the presence of an
MRF. Inhibition of pituitary MSH depletion either by an extract itself or by an
added substance (such as the tripeptide) is taken as a measure of MRIF activity.
If the MSH content of the pituitary is the same as controls (i.e., no change in
MSH content), this is interpreted as an inhibition of MSH release, or more pre-
cisely as an inhibition of the releasing factor (MRF) of MSH. This is in contradic-
tion to the results of Kastin et al., (48) who reported that hypothalamic extracts
which have MRIF activity increase pituitary MSH levels as a result of "direct"
inhibition of MSH release. In other words, in somewhat simplified terms, one idea
suggests that no change in pituitary MSH content is evidence for MRIF because
an MRF is blocked, and another suggests that a raise in pituitary MSH is evidence
for MRIF because normal MSH release is blocked. Which is valid? Is either valid?
It appears that the direct pituitary (frog) application assay (32) was developed
by Kastin et al. because L-Pro-L-Leu-Gly-HN2 was inactive in the other in vivo
(rat) assays (the same wherein hypothalamic extracts were reported (48), to be
active because of the presence of MRIF). It is puzzling that this tripeptide which
has been nominated as MRIF should not work in the same assay system wherein
an MRIF was first postulated by these same investigators. Since it is said that serum
(frog) inactivates the tripeptide (in doses as high as 10 mg) it seems surprising
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tous that these workers could report (47) the "presence of increased amounts"
of L-Pro-L-Leu-Gly-NH2 in rat plasma. (To our knowledge this would be one of
the few reports of a hypothalamic factor being detectable in plasma). Celis et al.
(29) appear to have no problem in measuring MRIF activity of the tripeptide
in the rat in vivo (or in vitro). The results using the direct pituitary application
assay are certainly not impressive since changes in melanophore index are minimal
in response to the tripeptide. Also, the melanocyte indices that have been reported
(e.g., 3.76 ± 0.07) by these workers are impossible to obtain by any presently
known visual or objective methods (1).
Our view of the "positive" MRIF-like activities of various peptides in our own
and other laboratories is that they probably represent the effects of poorly under-
stood changes in the microenvironment which may or may not be of normal physio-
logical significance (55). It would seem that a more readily interpreted in vivo
assay for MSH release is needed, preferably one in which changes in MSH levels
could be measured in the blood of an animal which was minimally manipulated
surgically. In the in vitro assay, much more information about microenvironmental
effects is clearly needed before one can be reasonably certain that the measured
effect on MSH release is a direct result of the substance tested and not an indirect
effect resulting from a change in the microenvironment. For example, Kastin et
al. have reported (56) a "mass action-type direct feedback control of pituitary
release" of MSH. Under similar and related experimental conditions we have been
unable to support this "mini" feedback hypothesis; indeed, we have obtained essen-
tially opposite results (55). Also, apparently a number of investigators (including
ourselves [14, 20]) may have been misled by the use of crude hypothalamic ex-
tracts. The so-called MRIF activity of these extracts is possibly due to nothing
more than a decreased concentration of MSH resulting from enzymatic degradation
of the hormone. Our results using either boiled or acid-extracted hypothalamic
extracts in vitro, fail to provide any support for the existence of a hypothalamic
MRIF or (MRF). In fact, it is now being suggested that the activity of hypothala-
mic extracts with regard to their effects on MSH release may depend upon the
relative amounts of MRF and MRIF in the extracts which are affected by previous
treatment of the particular extract (57).
Underlying all of these difficulties of interpretation is the nagging question of
whether control of MSH release from the pars intermedia is under a neurosecretory
control or an adrenergic control. Evidence is available in support of both inter-
pretations, but it seems to us that neither control mechanism is firmly established.
Certainly more work is needed to determine whether one or both are either singly
or together involved. Basic to all of these questions is whether MSH secretion is
under inhibitory control only or whether both inhibitory and release control
mechanisms are important. The evidence for inhibitory control of MSH release
appears to be firmly established from both the in vivo and in vitro data, but
whether a releasing factor is also operative in the control of MSH release is still
uncertain. To the best of our knowledge, only Taleisnik and co-workers have any
strong evidence for such a control, and apparently other investigators have been
unable to provide support for its existence.
Until these and other questions are acceptably answered theories about the
nature of MRIF (whether a peptide or some other substance) will have to be ac-
ceptably tested. A disturbing aspect of these attempts to elucidate the structure(s)
of these hypothalamic factors is the use of the word "hormone" rather than "fac-
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tor" in the designation of these hypothalamic substances before they have qualified
for such identity by normal endocrinological rules.
The most promising studies on the control of MSH secretion relate to the cellular
mechanisms involved in release of this hormone from the pars intermedia cell. The
demonstration of a Ca2+ ion requirement for hormone release was not unexpected
since nearly all cellular secretory events require Ca2+ (58) in what has been re-
ferred to as a "stimulus-secretion coupling" which has been likened to the "excita-
tion-contraction coupling" in muscle (59). Most important was the demonstration
of a K+ ion requirement for MSH release which had previously only been theorized
(60) as a possibility for the mammotrophs of the pars distalis, which like pars
intermedia cells are under an inhibitory influence by the hypothalamus. These re-
sults relative to the K+ ion suggested a possible role for a Na+-K+ pump (active
transport) system and this was (in our opinion) confirmed by the demonstration
that ouabain (a cardiac glycoside) also inhibited MSH release. Of interest here
is the recent report that the use of ouabain resulted in the release of ACTH and
growth hormone from the rat pituitary (61). This result is consistent with earlier
studies on other secretory systems (see 13, for references). Although such data
appear at first contradictory, it must be emphasized here that they may actually
provide important clues to the mechanisms involved in "stimulatory" versus "in-
hibitory" secretory systems. Ouabain may cause an increased influx of Na+ (and
a possible sodium-dependent Ca2+ influx, 62) leading to membrane depolarization
which would then provide the stimulus for hormone secretion (63). On the other
hand, as suggested previously (13), inhibition of MSH release may result from
cellular hyperpolarization of previously "spontaneously depolarized" (64) pars in-
termedia cells resulting from K+ efflux concomitant with ouabain-inhibition of K+
influx.
Our results using cytochalasin B are consistent with numerous other studies
which have demonstrated that this drug is a potent inhibitor of cellular secretions
(21, 23, 24), including the "cytocrine" (secretory) activity of epidermal melano-
cytes (65, 66). Whether these findings really implicate a role for microfilaments
in hormone secretion remains to be shown. The failure to demonstrate "microtubu-
lar-microfilamentous structures" "connecting either the secretory granules with one
another or the granule with the cell membrane" certainly need not imply "an ab-
sence of a relationship in the pars intermedia" (67) since, to our knowledge, only
Lacy et al. (21) in his original observation on insulin-secreting cells has been so
fortunate to make such an observation. Such an event is not likely to be easily
captured in an electron micrograph (68).
Although there are many inconsistencies and unresolved problems concerning
the control of MSH secretion (69), these latter studies on the cellular mechanisms
regulating MSH release suggest that general answers relating to MSH and hormone
secretion in general may be resolved in the near future.
SUMMARY
Synthetic tocinamide and tocinoic acid, ring structures of oxytocin, reversibly
inhibit (at nanogram, or less, concentrations) the release of melanophore-stimu-
lating hormone (MSH) from the rat and hamster pituitary in vitro. These peptides
are less effective (on Bufo marinus and Rana catesbeiana) or totally without effect
(on Rana pipiens) on MSH release from the isolated amphibian pars intermedia.
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Oxytocin, lysine vasopressin, and ring structures of the vasopressins (pressinamide
and pressinoic acid) are without effect of MSH release in the animals studied. The
synthetic tripeptide side chain of oxytocin (L-Pro-L-Leu-Gly-NH2) is devoid of
in vitro MSH release inhibition in either the mammal or the frog.
Crude hypothalamic extracts from either the frog or the rat "appear" to re-
versibly inhibit in vitro MSH release. If, however, the extracts are heated to boiling
or acid extracted, inhibition of MSH release is not observed, suggesting enzymatic
or other reactions may be responsible for the loss of bioassayable MSH. The addi-
tion of MSH to crude hypothalamic extracts results in a loss of hormone activity.
It is, therefore, unclear whether hypothalamic extracts provide evidence for the
existence of a hypothalamic MSH release-inhibiting factor (MRIF). It remains
for further work to establish whether the ring structures of the neurohypophyseal
hormones can be considered as possible candidates for a natural vertebrate MRIF.
Both calcium and potassium ions are necessary for MSH release in vitro. Release
of the hormone is inhibited by ouabain and related cardiac glycosides suggesting
that a Na+-K+ pump (active transport) system is involved in MSH release. Cyto-
chalasin B, but not colchicine (or vinblastine and vincristine) is reversibly in-
hibitory to hormone release and suggests that a microfilament (rather than a
microtubular) system may be involved in the mechanism of acute release of MSH.
However, other actions of cytochalasin B on transport mechanisms or ionic fluxes
may account for its inhibition of MSH release. The relationships between an active
transport system, calcium ions, and a microfilament system in the control of MSH
release by hypothalamic substances, neurohypophyseal peptides, or related struc-
tures are still unclarified.
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